Bipolar Disorder Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AbbVie, Allergan, Novartis, Pfizer, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline Plc, J

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Bipolar Disorder pipeline constitutes 22+ key companies continuously working towards developing 22+ Bipolar Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Bipolar Disorder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bipolar Disorder Market.

The Bipolar Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Bipolar Disorder Pipeline Report: https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Bipolar Disorder treatment therapies with a considerable amount of success over the years.
• Bipolar Disorder companies working in the treatment market are Clexio Biosciences, Iltoo Pharma, SAGE Therapeutics, NeuroRx, Inc., Sumitomo Dainippon Pharma, AstraZeneca, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Novartis, Forest Laboratories, and others, are developing therapies for the Bipolar Disorder treatment
• Emerging Bipolar Disorder therapies in the different phases of clinical trials are- CLE-100, ILT101, Zuranolone, NRX101, NRX100, SEP-4199, Quetiapine fumarate (Seroquel) SR, risperidone, Ziprasidone/Geodon, Aripiprazole, iloperidone, Memantine, and others are expected to have a significant impact on the Bipolar Disorder market in the coming years.
• In May 2024, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage pharmaceutical company, announced today that its recently completed clinical trial for patients with suicidal bipolar depression showed a statistically significant safety advantage of NRX-101 over the standard of care comparator. Consequently, the Company believes that the demonstrated reduction in akathisia, along with comparable antidepressant efficacy, provides a basis for Accelerated FDA Approval of NRX-101.
• In August 2023, Alzamend Neuro, a US-based biopharma company, has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to begin a Phase IIa trial of its AL001 candidate for treating bipolar disorder.

Bipolar Disorder Overview
Bipolar disorder is a mental condition that produces abnormal swings in mood, energy, activity level, focus, and the capacity to do daily chores. It was originally known as manic-depressive sickness or manic depression. Extreme mood fluctuations, characterized by emotional highs (mania or hypomania) and lows (depression), are caused by this disorder.

Get a Free Sample PDF Report to know more about Bipolar Disorder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Bipolar Disorder Drugs Under Different Phases of Clinical Development Include:
• CLE-100: Clexio Biosciences
• ILT101: Iltoo Pharma
• Zuranolone: SAGE Therapeutics
• NRX101: NeuroRx, Inc.
• NRX100: NeuroRx, Inc.
• SEP-4199: Sumitomo Dainippon Pharma
• Quetiapine fumarate (Seroquel) SR: AstraZeneca
• risperidone: Johnson & Johnson
• Ziprasidone/Geodon: Pfizer
• Aripiprazole: Bristol-Myers Squibb
• iloperidone: Novartis
• Memantine: Forest Laboratories

Bipolar Disorder Route of Administration
Bipolar Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Bipolar Disorder Molecule Type
Bipolar Disorder Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Bipolar Disorder Pipeline Therapeutics Assessment
• Bipolar Disorder Assessment by Product Type
• Bipolar Disorder By Stage and Product Type
• Bipolar Disorder Assessment by Route of Administration
• Bipolar Disorder By Stage and Route of Administration
• Bipolar Disorder Assessment by Molecule Type
• Bipolar Disorder by Stage and Molecule Type

DelveInsight's Bipolar Disorder Report covers around 22+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Bipolar Disorder product details are provided in the report. Download the Bipolar Disorder pipeline report to learn more about the emerging Bipolar Disorder therapies at:
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Bipolar Disorder Therapeutics Market include:
Key companies developing therapies for Bipolar Disorder are - AbbVie Inc., Allergan PLC, AstraZeneca Plc, Eli Lilly and Company, GlaxoSmithKline Plc, Janssen Pharmaceuticals Inc., Novartis AG, Otsuka Holdings Co. Ltd, Pfizer Inc., and others.

Bipolar Disorder Pipeline Analysis:
The Bipolar Disorder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Bipolar Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bipolar Disorder Treatment.
• Bipolar Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bipolar Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bipolar Disorder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Bipolar Disorder drugs and therapies-
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Disorder Pipeline Market Drivers
• Demand of new technologies, Increase in the awareness regarding mental disorders are some of the important factors that are fueling the Bipolar Disorder Market.

Bipolar Disorder Pipeline Market Barriers
• However, fewer randomized controlled trials (RCTs) of acute Bipolar Depression, strict pricing and reimbursement policies and other factors are creating obstacles in the Bipolar Disorder Market growth.

Scope of Bipolar Disorder Pipeline Drug Insight
• Coverage: Global
• Key Bipolar Disorder Companies: Clexio Biosciences, Iltoo Pharma, SAGE Therapeutics, NeuroRx, Inc., Sumitomo Dainippon Pharma, AstraZeneca, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Novartis, Forest Laboratories, and others
• Key Bipolar Disorder Therapies: CLE-100, ILT101, Zuranolone, NRX101, NRX100, SEP-4199, Quetiapine fumarate (Seroquel) SR, risperidone, Ziprasidone/Geodon, Aripiprazole, iloperidone, Memantine, and others
• Bipolar Disorder Therapeutic Assessment: Bipolar Disorder current marketed and Bipolar Disorder emerging therapies
• Bipolar Disorder Market Dynamics: Bipolar Disorder market drivers and Bipolar Disorder market barriers

Request for Sample PDF Report for Bipolar Disorder Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Bipolar Disorder Report Introduction
2. Bipolar Disorder Executive Summary
3. Bipolar Disorder Overview
4. Bipolar Disorder- Analytical Perspective In-depth Commercial Assessment
5. Bipolar Disorder Pipeline Therapeutics
6. Bipolar Disorder Late Stage Products (Phase II/III)
7. Bipolar Disorder Mid Stage Products (Phase II)
8. Bipolar Disorder Early Stage Products (Phase I)
9. Bipolar Disorder Preclinical Stage Products
10. Bipolar Disorder Therapeutics Assessment
11. Bipolar Disorder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Bipolar Disorder Key Companies
14. Bipolar Disorder Key Products
15. Bipolar Disorder Unmet Needs
16 . Bipolar Disorder Market Drivers and Barriers
17. Bipolar Disorder Future Perspectives and Conclusion
18. Bipolar Disorder Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Bipolar Disorder Market https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Bipolar Disorder Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Bipolar Disorder Epidemiology https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Bipolar Disorder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports Offered By DelveInsight:

Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market
DelveInsight's "Idiopathic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Idiopathic Thrombocytopenic Purpura, historical and forecasted epidemiology as well as the Idiopathic Thrombocytopenic Purpura market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Inguinal Hernia Market
https://www.delveinsight.com/report-store/inguinal-hernia-market
DelveInsight's "Inguinal Hernia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Inguinal Hernia, historical and forecasted epidemiology as well as the Inguinal Hernia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Charcot-marie-tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.